Psoriatic arthritis study using ultrasound to track activity
Part of Bones, joints & muscles, Skin clinical trials.
This study uses power Doppler ultrasound to classify and measure how active your psoriatic arthritis is. It may help doctors better understand and treat your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriatic arthritis as diagnosed by a doctor using standard criteria.
- You are willing to follow the study schedule, treatments, and tests.
- You can give your permission to be in the study.
- You have not had another type of arthritis in the past year.
- You do not have an active infection or a chronic infectious disease.
- You are not pregnant or breastfeeding, and you can tolerate having blood drawn.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether IL-17 inhibitor medications can reduce inflammation in tendons and ligaments that is not visible on the skin but can be detected with a special ultrasound. It may be an option for people with moderate to severe psoriasis who have not had enough relief from creams or light therapy.
This study looks at how psoriatic arthritis affects your daily life and how that relates to the severity of your condition. It aims to better understand the disease to improve future care.
This study uses special ultrasound imaging to look at the places where tendons attach to bone (called entheses) in people with psoriatic arthritis. The goal is to see how these images compare to those of healthy people, which may help doctors understand and monitor the condition better.
This trial studies people with psoriatic arthritis who have painful Achilles tendon insertion with signs of inflammation on ultrasound. It may help researchers better understand what drives tendon inflammation and how it can be treated.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.